Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name PBRM1 loss
Gene Variant Detail

PBRM1 loss (loss of function)

Relevant Treatment Approaches EZH2 inhibitor

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
PBRM1 loss melanoma sensitive unspecified CTLA4 antibody + unspecified PD-1 antibody Preclinical - Cell line xenograft Actionable In a preclinical study, knocking-out PBRM1 in melanoma cells sensitized cells to immune therapy consisted of anti-CTLA4 and anti-PD-1 antibodies in culture and in cell line xenograft models, potentially due to increased sensitivity to T cell-mediated cytotoxicity and a favorable tumor microenvironment (PMID: 29301958). 29301958
PBRM1 loss lung cancer sensitive PRT1419 + Sunitinib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of PRT1419 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). 38371625
PBRM1 loss lung cancer sensitive PRT2527 Preclinical - Cell line xenograft Actionable In a preclinical study, PRT2527 inhibited tumor growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). 38371625
PBRM1 loss lung cancer sensitive PRT2527 + Sunitinib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of PRT2527 and Sutent (sunitinib) inhibited tumor growth and tumor re-growth in a lung cancer cell line xenograft model with loss of PBRM1 (PMID: 38371625). 38371625